ClinicalTrials.gg
CompletedNCT00161850Updated May 21, 2015

FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years

A Phase 2 interventional study of Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) in Encephalitis, Tick-borne, sponsored by Pfizer. Completed at 25 sites in 2 countries. Open to participants aged 1 Year to 6 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-21.

Sponsored by Pfizer · Phase 2 and Interventional

Phase
Phase 2
Study type
Interventional
Enrollment
615
Allocation
Randomized
Ages
1 Year to 6 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the safety and immunogenicity of the third vaccination with one of three different concentrations of a TBE vaccine in all subjects who completed two vaccinations in one of the three treatment groups of Baxter study 199 (a dose-finding study to investigate the safety and immunogenicity of two vaccinations with FSME IMMUN NEW in healthy subjects aged 1 to 6 years).

02

Conditions studied

  • Encephalitis, Tick-borne
03

In context

Encephalitis, Tick-Borne

51 studies on the registry are indexed under Encephalitis, Tick-Borne; 9 are open to participants now.

This study's enrollment of 615 is above the median of 192 across 32 interventional studies indexed under Encephalitis, Tick-Borne.

Browse Encephalitis, Tick-Borne studies →

Lead sponsor

Pfizer is the lead sponsor of 3,334 studies on the registry; 149 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 391 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 6 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All volunteers who participated in Baxter study 199 and received two vaccinations will be invited to participate. Male and female children will be eligible for participation in this study if:

  • They received two vaccinations with one of the three different dosages of FSME IMMUN NEW during the course of Baxter study 199
  • Written from the legal guardian is available.

Exclusion criteria

Exclusion Criteria:

There are no specific exclusion criteria for this study entry. However volunteers will be assessed for eligibility to receive a third vaccination.

Volunteers will be excluded from vaccination and consecutive visits in this study if they:

  • Are not clinically healthy, (i. e. the physician would have reservations vaccinating with FSME IMMUN NEW outside the scope of a clinical trial)
  • Have already been administered a third TBE vaccination elsewhere after the two vaccinations in Baxter study 199
  • Have had an allergic reaction to one of the components of the vaccine since the last vaccination in Baxter study 199
  • Suffer from a disease (e.g. disease) or are undergoing a form of treatment (e.g. systemic , chemotherapeutics) that can be expected to influence immunological functions
  • Have received banked human blood or immunoglobulins within one month of study entry
  • Are known to be positive (a special HIV test is not required for the purpose of the study) since the last visit of Baxter study 199
  • Have had a vaccination against yellow fever and / or Japanese B-encephalitis since the last visit in Baxter study 199
  • Had received an new drug within 6 weeks prior to study start
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
615 participants
06

Study locations

25 sites
  • Grieskirchner Strasse 17
    Wels, A-4600, Austria
  • Neuschwanstein Strasse 5
    Augsburg, D-86163, Germany
  • Marktplatz 33
    Bad Saulgau, D-88348, Germany
  • Hauptstrasse 9
    Bietigheim-Bissingen, D-74321, Germany
  • Salzgasse 11
    Calw, D-75365, Germany
  • Mohrenstrasse 8
    Coburg, D-96450, Germany
  • Bahnhofstrasse 1
    Elzach, D-79215, Germany
  • Rheinstrasse 1a
    Ettenheim, D-77955, Germany
  • Ehlerstrasse 17
    Friedrichshafen, D-88046, Germany
  • Peter-Seifert Strasse 5
    Gersfeld, D-36129, Germany
  • Solothumer Strasse 2
    Heilbronn, D-74072, Germany
  • Hauptstrasse 240
    Kehl, D-77694, Germany
  • Schwarzwald Strasse 20
    Kirchzarten, D-79199, Germany
  • Altoettinger Strasse 3
    Landsberg, D-86899, Germany
  • Rastatter Strasse 7
    Mannheim-Secken, 68239, Germany
  • Wilhelmstrasse 25
    Metzingen, D-72555, Germany
  • Dohmbuehler Strasse 8
    Nuernberg, D-90449, Germany
  • Glogauer Strasse 15
    Nuernberg, D-90473, Germany
  • Tuchbergstrasse 2
    Oberndorf/Neckar, D-78727, Germany
  • Wilhelmstrasse 7
    Offenburg, D-77654, Germany
  • Asternweg 11a
    Offenburg, D-77656, Germany
  • Bergstrasse 27
    Rottweil, D-78628, Germany
  • Berneckstrasse 19
    Schramberg, D-78713, Germany
  • Hauptstrasse 11
    Tegernsee, D-83681, Germany
  • Broner Platz 6
    Weingarten, D-88250, Germany
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00161850
Lead sponsor
Pfizer
First posted
Sep 13, 2005
Start date
Feb 2002
Completion
Aug 2002
Last update
May 21, 2015

Study contacts

Baxter BioScience Investigator
principal investigator · Baxter Healthcare Corporation
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tick-borne encephalitis vaccine

Start the discussion